JPWO2023043978A5 - - Google Patents
Info
- Publication number
- JPWO2023043978A5 JPWO2023043978A5 JP2024517044A JP2024517044A JPWO2023043978A5 JP WO2023043978 A5 JPWO2023043978 A5 JP WO2023043978A5 JP 2024517044 A JP2024517044 A JP 2024517044A JP 2024517044 A JP2024517044 A JP 2024517044A JP WO2023043978 A5 JPWO2023043978 A5 JP WO2023043978A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- hil
- polypeptide
- acid sequence
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245523P | 2021-09-17 | 2021-09-17 | |
| US63/245,523 | 2021-09-17 | ||
| PCT/US2022/043762 WO2023043978A2 (en) | 2021-09-17 | 2022-09-16 | Caix targeting il-12 fusion proteins and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534468A JP2024534468A (ja) | 2024-09-20 |
| JP2024534468A5 JP2024534468A5 (https=) | 2025-09-04 |
| JPWO2023043978A5 true JPWO2023043978A5 (https=) | 2025-09-04 |
Family
ID=85603506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517044A Pending JP2024534468A (ja) | 2021-09-17 | 2022-09-16 | Ｃａｉｘ標的化ｉｌ－１２融合タンパク質およびそれらの使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240392031A1 (https=) |
| EP (1) | EP4402158A4 (https=) |
| JP (1) | JP2024534468A (https=) |
| KR (1) | KR20240161081A (https=) |
| CN (1) | CN118369331A (https=) |
| AU (1) | AU2022345103A1 (https=) |
| CA (1) | CA3232632A1 (https=) |
| IL (1) | IL311442A (https=) |
| MX (1) | MX2024003275A (https=) |
| WO (1) | WO2023043978A2 (https=) |
| ZA (1) | ZA202402034B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111630062A (zh) | 2017-11-28 | 2020-09-04 | 中外制药株式会社 | 具有可调节的配体结合活性的配体结合分子 |
| WO2025012105A2 (en) * | 2023-07-07 | 2025-01-16 | Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern | Muteins of human interleukin 12 |
| WO2025101133A1 (en) * | 2023-11-10 | 2025-05-15 | Agency For Science, Technology And Research | Interleukin-12 variants and medical uses thereof |
| WO2025136986A2 (en) | 2023-12-18 | 2025-06-26 | Genzyme Corporation | Il-12 loss of potency muteins |
| WO2025205534A1 (ja) * | 2024-03-25 | 2025-10-02 | 積水メディカル株式会社 | 免疫測定方法、精度管理方法、標準試料及び免疫測定試薬 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0620648B1 (pt) * | 2005-12-30 | 2022-12-20 | Merck Patent Gesellschaft Mit Beschrãnkter Haftung | Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma |
| US20210130430A1 (en) * | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| IL297186A (en) * | 2020-04-17 | 2022-12-01 | Univ Leland Stanford Junior | Transgenic il-12 and il-23 polypeptides and their uses |
-
2022
- 2022-09-16 WO PCT/US2022/043762 patent/WO2023043978A2/en not_active Ceased
- 2022-09-16 AU AU2022345103A patent/AU2022345103A1/en active Pending
- 2022-09-16 EP EP22870726.1A patent/EP4402158A4/en active Pending
- 2022-09-16 IL IL311442A patent/IL311442A/en unknown
- 2022-09-16 CA CA3232632A patent/CA3232632A1/en active Pending
- 2022-09-16 JP JP2024517044A patent/JP2024534468A/ja active Pending
- 2022-09-16 CN CN202280076070.8A patent/CN118369331A/zh active Pending
- 2022-09-16 KR KR1020247012576A patent/KR20240161081A/ko active Pending
- 2022-09-16 MX MX2024003275A patent/MX2024003275A/es unknown
-
2024
- 2024-03-12 ZA ZA2024/02034A patent/ZA202402034B/en unknown
- 2024-03-15 US US18/607,049 patent/US20240392031A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113260379B (zh) | 蛋白酶可切割的双特异性抗体及其用途 | |
| ES2801873T3 (es) | Anticuerpo de PDL-1, composición farmacéutica del mismo y sus usos | |
| ES2747749T3 (es) | Anticuerpos multiespecíficos | |
| CN104341529B (zh) | 带有DARPin的双特异性嵌合蛋白 | |
| CA3199566A1 (en) | Anti-cd276 antibody, antibody-drug conjugate, and use thereof | |
| JP2021522162A5 (https=) | ||
| CN111148761A (zh) | 多特异性抗体及其制备和使用方法 | |
| EP2784091B1 (en) | Bispecific anti-cMet/anti-Her2 antibodies | |
| WO2023174396A1 (zh) | 一种新型免疫调节剂的开发和应用 | |
| WO2020062155A1 (en) | Dual targeting antigen binding molecule | |
| JPWO2020146221A5 (https=) | ||
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| IL321280A (en) | Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof | |
| JPWO2021064137A5 (https=) | ||
| JPWO2023043978A5 (https=) | ||
| Müller et al. | Bispecific antibodies | |
| JPWO2019217332A5 (https=) | ||
| TW201902513A (zh) | 治療方法 | |
| US20240101701A1 (en) | Antibody-derived t cell activating technologies | |
| WO2023163087A1 (ja) | 抗変異ｃａｌｒ抗体と他の薬剤とを組み合わせてなる医薬 | |
| WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
| WO2025045018A1 (en) | Anti-gamma delta tcr antibodies and uses thereof | |
| WO2026057723A1 (en) | Claudin-1/egfr bispecific antibodies for targeted degradation | |
| WO2024032617A1 (zh) | 异多聚体蛋白质及其制备方法 | |
| WO2025190404A1 (zh) | 双特异性抗体、抗体药物偶联物及其应用 |